SEROPREVALENCE OF SARS-CoV-2 SERUM IgG ANTIBODY IN ADULT POPULATION OF SIALKOT CITY, PAKISTAN: A CROSS- SECTIONAL STUDY
DOI:
https://doi.org/10.59058/jaimc.v20i2.32Keywords:
Sero-prevalence; COVID-19; SARs-CoV-2 IgG antibody; ECLIA; Sialkot, Herd immunity; PandemicAbstract
Background and Objectives: Seroprevalence studies provide necessary data on extent of SARS-CoV-2 infection in a community. Identifying immune response of individuals exposed to this virus is one way of assessing community disease transmission and herd immunity. The aim of this study was to measure SARS- CoV-2 IgG antibody among adult individuals of Sialkot city overall and stratified by age and sex. Additionally, to describe COVID-19 presenting symptoms and its duration in these participants.
Methods: This descriptive, cross-sectional study was undertaken in Sialkot city, where 453 participants completed in-person interview on COVID-19 symptoms, socio-demographic profile and provided 5ml blood sample for SARS-CoV-2 IgG antibody testing using electro-chemiluminescent immunoassay (ECLIA) technique. SPSS version 22 was utilized for data management and analysis. Sero-prevalence was calculated as percent of reactive for IgG among all tested. Chi-squared test was used for determining statistical significance with p <0.05 was considered significant.
Results: Overall, sero-prevalence of SARS-CoV-2 IgG antibody among adults in Sialkot was 64%. Almost, 134(29.5%) of these positive for COVID-19 IgG antibody had antibody titres level 15 units/dl or above. Three out of every four individuals reported one or more symptoms of COVID-19 dry cough (17%), fever (30%) loss of taste (6%), sore throat (5%) and anosmia (4.6%).
Conclusion: Almost two-third of adult population in Sialkot city had SARS-CoV-2 IgG antibody during 2021 survey that implies that herd immunity level for COVID-19 is achieved and negligible number of COVID-19 cases reported in Sialkot city supports this evidence.
References
Binti Hamzah FA, Lau C, Nazri H, Ligot DV, Lee G,Tan CL, et al. CoronaTracker: Worldwide COVID-19 Outbreak Data Analysis and Prediction. [Submitted]. Bull World Health Organ. E-pub: 19 March 2020. doi: http://dx.doi.org/10.2471/BLT.20.255695
Bendavid E, Mulaney B, Sood N, Shah S, Bromley- Dulfano R, Lai C, et al. COVID-19 antibody seropre- valence in Santa Clara County, California. Int J Epi- demiol, 2021, 410–419. doi: 10.1093/ije/dyab010
Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Y, et al. Serology for SARS-CoV-2: appre- hensions, opportunities, and the path forward. Sci Immunol. 2020;5(47):eabc6347
Centers for disease control and prevention (CDC) Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings, available at: https://www.cdc.gov/coronavirus/2019-ncov/lab/ resources/antibody-tests-guidelines.html,accessed on 01 November 2021.
Government of the Pakistan. Punjab Cases Details. Available at: www. https://covid.gov.pk/ stats/ punjab accessed on 30 August 2022.
Randolph HE, Barreiro LB. Herd immunity: under- standing COVID-19. Immunity. 2020;52(5): 737–741.
Slot E, Hogema BM, Reusken CB, Reimerink JH, Molier M, Karregat JH, et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak. [Updated 2020]. [Accessed June 5, 2020]
Javed W, Abidi, SHB, Baqar JB. Seroprevalence and characteristics of Coronavirus Disease (COVID-19) in workers with non-specific disease symptoms. BMC Infectious Diseases 2022; 22:481. https:// doi.org/ 10. 1186/ s12879-022-07461-9
Ahsan AM, Shahzad K, Masood M, Umar M, Abbasi F, Hafeez A. COVID-19 seroprevalence in Pakistan: a cross-sectional study. BMJ Open 2022; 12:e055381. doi:10.1136/bmjopen-2021-055381
Batool H, Chughtai O, Khan MD, Chughtai AS, Ashraf S, Khan MJ. Seroprevalence of COVID-19 IgG anti- bodies among healthcare workers of Pakistan: a cross- sectional study assessing exposure to COVID-19 and identification of high-risk subgroups. BMJ Open 2021;11:e046276. doi:10.1136/bmjopen-2020-046276
Naiyar I, Anjum AF, Khalid AM, Noor I, Abdullah MS, Anwar MZ. Seroprevalence of COVID-19 and associated factors in a medical institution in Pakistan. Journal of Taibah University Medical Sciences 2021; 64(4):619-23. https://doi.org/10.1016/j.jtumed. 2021. 04.004
Inbaraj LR, George CE, Chandrasingh S. Seropreva- lence of COVID-19 infection in a rural district of South India: A population-based seroepidemiological study. PLoS ONE 2021; 16(3): e0249247. https://doi.org/ 10. 1371/journal. pone.0249247
National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immuno- assays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. 2020; 20 (12): 1390– 400. https://doi.org/10.1016/S1473-3099(20)30634- 4 PMID: 32979318
Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis. Diagnostics (Basel) 2020; 10(5):319.
Vogel G. First antibody surveys draw fire for quality, bias. Science. 2020;368 (6489):350–351
Torres MKS, Lopes FT, de Lima1 ACR, Lima CNC, Brito WRDS, Santos BCD, et al. Seroprevalence and risk factors for COVID-19 in the metropolis of the Brazilian Amazon. Scientific Reports 2022; 12:8571. https://doi.org/10.1038/s41598-022-12629-z
Shakiba M, Hashemi Nazari SS, Mehrabian F, Rezvani SM, Ghasempour Z, Heidarzadeh A. Seroprevalence of COVID-19 virus infection in Guilan province, Iran. [Updated 2020]. [Accessed June 5, 2020].
Haq M, Rehman A, Ahmad J, Zafar U, Ahmed S, Khan MA, et al. SARS-CoV-2: big seroprevalence data from Pakistan—is herd immunity at hand? Infection 2021; 49:983–988. https://doi.org/10.1007/s15010- 021-01629-2
Wang C , Hornby PW , Hayden FG , Gao GF.A novel coronavirus outbreak of global health concern. Lancet [published online January 24, 2020].DOI: 10.1016 / S0140-6736 (20) 30185-9
Song SK, Lee DH, Nam JH, Kim KT, Do JS, Kang DW, Kim SG, Cho MR. IgG Seroprevalence of COVID- 19 among Individuals without a History of the Corona- virus Disease Infection in Daegu, Korea. J Korean Med Sci. 2020 Jul 27;35(29):e269. doi: 10.3346/ jkms. 2020.35.e269. PMID: 32715672; PMCID: PMC738 4903.
Doi A, Iwata K, Kuroda H, Hasuike T, Nasu S, Kanda A, et al. Estimation of seroprevalence of novel corona- virus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: a cross-sectional study. [Updated 2020]. [Accessed June 5, 2021].
Breedon AME, Saldanha RJ, Salisbury RL, Metzger DE, Werry MP, McPherson CJ, et al. COVID-19 Sero- prevalence and Active Infection in an Asymptomatic Population. Front. Med 2021; 8:749732. doi: 10.3389/ fmed.2021.749732
Alsuwaidi AR, Hosani AIA, Al –Memari S, Narchi H, Wareth AL, Kamal H, et al. Seroprevalence of COVID-19 infection in the Emirate of Abu Dhabi, United Arab Emirates: a population-based cross-sec- tional study. International Journal of Epidemiology 2021, 1077–1090 doi: 10.1093/ije/dyab077
Bawa MS, Desale AV, Pandve HT, Nimbalkar AV, Patil TV, Gophane LP, et al. Population based repeat cross-sectional seroprevalence survey of SARS-COV-2 IgG antibodies in Pimpri Chinchwad municipal cor- poration area, Maharashtra, India. J Family Med Prim Care 2022;11:2789-93.
Leslie M. T cells found in coronavirus patients ‘bode well’for long-term immunity. Science. 2020; 368(6493): 809–810
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 JAIMC
This work is licensed under a Creative Commons Attribution 4.0 International License.
The articles published in this journal come under creative commons licence Attribution 4.0 International (CC BY 4.0) which allows to copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially under following terms.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
The editorial board of the Journal strives hard for the authenticity and accuracy of the material published in the Journal. However, findings and statements are views of the authors and do not necessarily represent views of the Editorial Board. Many software like (Google Maps, Google Earth, Biorender (free version)) restricts the free distribution of materials prepared using these softwares. Therefore, authors are strongly advised to check the license/copyright information of the software used to prepare maps/images. In case of publication of copyright material, the correction will be published in one of the subsequent issues of the Journal, and the authors will bear the printing cost.
